{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+BRAF+Mutant+Cancers&page=2", "query": { "condition": "Advanced BRAF Mutant Cancers", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+BRAF+Mutant+Cancers&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-25T00:18:17.204Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02974725", "title": "A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer", "Melanoma" ], "interventions": [ { "name": "LXH254", "type": "DRUG" }, { "name": "LTT462", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 241, "start_date": "2017-02-24", "completion_date": "2024-04-24", "has_results": false, "last_update_posted_date": "2025-04-13", "last_synced_at": "2026-07-25T00:18:17.204Z", "location_count": 6, "location_summary": "San Diego, California • San Francisco, California • Boston, Massachusetts + 3 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02974725" }, { "nct_id": "NCT03543969", "title": "Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Melanoma (Skin)", "Skin Cancer", "Skin Melanoma", "Skin Carcinoma" ], "interventions": [ { "name": "Encorafenib", "type": "DRUG" }, { "name": "Binimetinib", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2018-06-14", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-07-25T00:18:17.204Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03543969" }, { "nct_id": "NCT03415126", "title": "A Study of ASN007 in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer", "Malignancy", "Neoplasia", "Neoplasm", "Neoplasm Metastasis", "Colon Cancer", "Colonic Neoplasms", "Colon Cancer Liver Metastasis", "Metastatic Cancer", "Metastatic Melanoma", "Metastatic Colon Cancer", "Metastatic Lung Cancer", "Non Small Cell Lung Cancer Metastatic", "Pancreatic Cancer", "Pancreas Cancer", "Pancreas Adenocarcinoma", "Pancreas Neoplasm", "Metastatic Nonsmall Cell Lung Cancer", "Metastatic Pancreatic Cancer" ], "interventions": [ { "name": "ASN007: ascending doses", "type": "DRUG" }, { "name": "ASN007 RD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Asana BioSciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2018-01-19", "completion_date": "2020-06-30", "has_results": false, "last_update_posted_date": "2020-07-09", "last_synced_at": "2026-07-25T00:18:17.204Z", "location_count": 5, "location_summary": "Tampa, Florida • Boston, Massachusetts • Houston, Texas + 1 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03415126" }, { "nct_id": "NCT01512251", "title": "BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "BRAF Mutant Metastatic Melanoma" ], "interventions": [ { "name": "BKM120 Combined with Vemurafenib (PLX4032)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2012-06-09", "completion_date": "2017-03-21", "has_results": true, "last_update_posted_date": "2020-08-17", "last_synced_at": "2026-07-25T00:18:17.204Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01512251" }, { "nct_id": "NCT01616199", "title": "Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced BRAF-mutant Cancers" ], "interventions": [ { "name": "PX-866", "type": "DRUG" }, { "name": "vemurafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cascadian Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2012-08", "completion_date": "2015-03", "has_results": false, "last_update_posted_date": "2018-05-16", "last_synced_at": "2026-07-25T00:18:17.204Z", "location_count": 5, "location_summary": "Tampa, Florida • New York, New York • Philadelphia, Pennsylvania + 2 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01616199" }, { "nct_id": "NCT01245062", "title": "GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "GSK1120212", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 322, "start_date": "2010-11-22", "completion_date": "2016-12-16", "has_results": true, "last_update_posted_date": "2018-04-05", "last_synced_at": "2026-07-25T00:18:17.204Z", "location_count": 13, "location_summary": "Tucson, Arizona • Fort Myers, Florida • Athens, Georgia + 10 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Athens", "state": "Georgia" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT01245062" }, { "nct_id": "NCT01362296", "title": "An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer, Non-Small Cell" ], "interventions": [ { "name": "GSK1120212", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 134, "start_date": "2011-09", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2014-07-11", "last_synced_at": "2026-07-25T00:18:17.204Z", "location_count": 25, "location_summary": "Scottsdale, Arizona • Orange, California • Aurora, Colorado + 20 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Athens", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01362296" }, { "nct_id": "NCT01897116", "title": "A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Hydroxychloroquine (HCQ)", "type": "DRUG" }, { "name": "Vemurafenib (VEM)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2013-06", "completion_date": "2016-10-05", "has_results": false, "last_update_posted_date": "2020-05-29", "last_synced_at": "2026-07-25T00:18:17.204Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01897116" }, { "nct_id": "NCT01320085", "title": "A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "BRAF or NRAS Mutant Metastatic Melanoma" ], "interventions": [ { "name": "MEK162", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 183, "start_date": "2011-03-24", "completion_date": "2023-02-06", "has_results": true, "last_update_posted_date": "2024-01-24", "last_synced_at": "2026-07-25T00:18:17.204Z", "location_count": 10, "location_summary": "Fayetteville, Arkansas • Tampa, Florida • Portland, Oregon + 3 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Tampa", "state": "Florida" }, { "city": "Portland", "state": "Oregon" }, { "city": "Portland", "state": "Oregon" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01320085" }, { "nct_id": "NCT01777776", "title": "Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced Metastatic BRAF Mutant Melanoma" ], "interventions": [ { "name": "LEE011", "type": "DRUG" }, { "name": "LGX818", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Array BioPharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2013-07", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2016-09-13", "last_synced_at": "2026-07-25T00:18:17.204Z", "location_count": 5, "location_summary": "Aurora, Colorado • Detroit, Michigan • New York, New York + 2 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Portland", "state": "Oregon" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01777776" } ] }